← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Retatrutide × Cagrilintide × 2 of 4 selected View comparison

Retatrutide

Triple receptor agonist

Remove
VS

Cagrilintide

Long-acting amylin analogue

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target RetatrutideCagrilintide
✓ —
✓ —
✓ —
— ✓

What These Compounds Share

Shared research line

All selected compounds are catalogued under Metabolic.

Shared pathway tags
Metabolic
Shared research areas
Obesity

Key Differences

Retatrutide GLP-1R and GIPR and GCGR are direct targets of Retatrutide that none of the other selected compounds share. Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.
Cagrilintide AMYLIN is a direct target of Cagrilintide that none of the other selected compounds share. Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.

Compound Detail

Retatrutide
What is it?
A lab-made peptide designed to activate three metabolic hormone receptors at once (GLP-1, GIP and glucagon) to help the body manage blood sugar, appetite and energy use.
What are people researching/using it for?
Mainly researched for weight loss and improving blood sugar control.
Other uses being trialed
Type 2 diabetesFatty liver disease
Worth knowing
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A single peptide engineered to activate GIP, GLP-1 and glucagon receptors simultaneously.
Synthetic acylated peptide · Synthetic analogue
Also known as: LY3437943
Primary Targets & Biological System
Incretin / metabolic / glucagon signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A single peptide engineered to activate three receptors at once: GLP-1R and GIPR (the two incretin receptors that respond to nutrient intake, central to how the body regulates insulin secretion and appetite) plus GCGR, the glucagon receptor -- usually associated with raising blood sugar and increasing energy expenditure rather than lowering it. Combining incretin agonism with glucagon-receptor agonism is the specific pharmacological rationale distinguishing retatrutide from single- or dual-receptor agonists: in Phase 2 human trials this combination was associated with reductions in body weight and improved glucose regulation. The relative contribution of the GCGR component specifically, versus the shared GLP-1R/GIPR activity, has not been isolated in human studies to date.
Research Areas
ObesityEnergy balanceGlucose metabolismType 2 diabetesMetabolic diseaseHepatic/metabolic outcomes
Research Profile
Human administration: Extensive Human observational: Available Preclinical: Available
Pharmacokinetics
Approximately 6 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.
Considerations
Research Limitations
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Fatty liver disease (MASLD/NAFLD)
Reductions in liver fat have been reported as a secondary finding in retatrutide obesity trials -- an active research direction, not a separate approved indication.
Obstructive sleep apnea
Investigated as a downstream effect of significant weight loss rather than a direct mechanism of its own; research in this specific population is ongoing.
Availability & Sources
Current Vital Edge Testing
Batch 2 (30mg) · tested Oct 2026 · 99.834% purity, 33.22mg content Purity/ID report
Batch 1 (30mg) Purity/ID report
Available As (Vital Edge Science)
Retatrutide — 10mg · A$109.95 A$119.95 Retatrutide — 30mg · A$299.95 A$319.95
Browse products →
View Research Sources (1) →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine, 2023 · Human Human · Phase 2 obesity trial participants · Subcutaneous · DOI 10.1056/NEJMoa2301972

Supports GIP/GLP-1/glucagon receptor agonism and the ~6-day half-life used on this record.

Supports: primary_targets, human_half_life, mechanism_summary

Cagrilintide
What is it?
A long-acting version of a natural hormone (amylin) that works alongside insulin to control appetite.
What are people researching/using it for?
Mainly studied for weight loss, often alongside GLP-1 medications.
Other uses being trialed
Combination therapy research alongside semaglutide/tirzepatide for obesity
Worth knowing
Often studied in combination with GLP-1 agonists rather than as a standalone agent.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Long-acting amylin analogue investigated for effects on satiety, food intake and metabolic physiology.
Acylated peptide analogue · Synthetic analogue
Primary Targets & Biological System
Amylin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A long-acting analogue of amylin, a hormone co-released with insulin from the pancreas after eating. Amylin receptor activation is associated with slowed gastric emptying and central signalling that promotes satiety, working through a mechanism distinct from -- but often studied alongside -- the incretin pathway that GLP-1/GIP agonists use. Because amylin and GLP-1 signalling act on different receptor systems, cagrilintide is frequently investigated in combination with GLP-1 agonists rather than as a mechanistic substitute for them.
Research Areas
ObesityAppetiteSatietyEnergy intakeMetabolic research
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
159-195 hours (roughly 6.6-8.1 days), dose-dependent
Reported in a randomized Phase 1b trial (0.16-4.5 mg SC weekly doses, co-administered with semaglutide 2.4 mg); median Tmax 24-72 h, exposure proportional to dose.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.
Considerations
Research Limitations
Often studied in combination with GLP-1 agonists rather than as a standalone agent.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
Cagrilintide · A$159.95 A$179.95
Browse products →
View Research Sources (1) →
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
The Lancet, 2021 · Human Human · 95 exposed adults (96 randomized), phase 1b multiple-ascending-dose trial, BMI 27-39.9 · Subcutaneous, once weekly · PMID 33894838 · DOI 10.1016/S0140-6736(21)00845-X

Half-life 159-195h, median Tmax 24-72h, exposure proportional to dose; did not affect semaglutide exposure/elimination.

Supports: human_half_life

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.